A, J., R, R., C, D., B, S., M, G., A, S., . . . MNN, P. (2026). Drug repurposing in KRAS G12C-mutant NSCLC: A focus on resistance mechanisms and clinical strategies. Naunyn-Schmiedeberg's archives of pharmacology. https://doi.org/10.1007/s00210-026-05533-0
Chicago Style (17th ed.) CitationA, Jain, et al. "Drug Repurposing in KRAS G12C-mutant NSCLC: A Focus on Resistance Mechanisms and Clinical Strategies." Naunyn-Schmiedeberg's Archives of Pharmacology 2026. https://doi.org/10.1007/s00210-026-05533-0.
MLA (9th ed.) CitationA, Jain, et al. "Drug Repurposing in KRAS G12C-mutant NSCLC: A Focus on Resistance Mechanisms and Clinical Strategies." Naunyn-Schmiedeberg's Archives of Pharmacology, 2026, https://doi.org/10.1007/s00210-026-05533-0.
Warning: These citations may not always be 100% accurate.
